This included contributions from subsets previously reported to be involved in MS pathogenesis and affected by alemtuzumab treatment (transitional, naïve, double‐negative, unswitched memory and switched memory B cells) as well as novel subsets, particularly IgA+CD20+, IgG1+ and IgG2+ B cells. Here, CD79A is linked to myeloid sarcoma.